Krystal Biotech (KRYS) Q2 FY26 earnings call

Krystal Biotech delivered a strong Q2 FY26, driven by robust U.S. VYJUVEK sales and significant pipeline advancements. While international revenue was impacted by German pricing reserves, underlying demand remains strong, and the company is actively navigating market-specific access challenges. The clinical pipeline is progressing with multiple registrational studies nearing readouts and new trials planned for 2027, positioning Krystal to evolve into a multi-product gene therapy company.